Padang City

Researchers are evaluating whether the medicine tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after they were last seen well. This study focuses on people who had a stroke caused by a clot blocking blood flow in the brain and who have imaging showing brain tissue that can still be saved. Participants should not be planning to receive a procedure to remove the clot and must have a pre-stroke disability level of 0 or 1 on the modified Rankin Scale. Participants are randomly placed into two groups. One group receives a single injection of tenecteplase into a vein, while the other group receives standard medical care. The study includes adults aged 18 and over who had an acute stroke or woke up with stroke symptoms more than 4.5 hours ago. Imaging with MRI or CT is used to confirm eligibility. The study lasts about three months, starting with a hospital stay of about one week. During the study, participants have seven clinical examinations or visits to monitor their recovery and health. The last two visits may be done from home to allow remote assessments. Researchers use the modified Rankin Scale to measure disability or dependence in daily activities at 90 days after treatment. They also monitor for any side effects or health changes to compare the effects of tenecteplase against standard care.

The HYIMPACT study is a large, observational research project across seven Asian countries designed to understand how Nebilet (nebivolol) works in people with high blood pressure, also called hypertension. It focuses on how Nebilet affects blood pressure control over time, treatment adherence, quality of life, prescription habits, and heart-related outcomes. The study includes about 5,000 adults with newly diagnosed or uncontrolled hypertension, some of whom may have other heart-related conditions. Participants will either start Nebilet treatment or have been on it for no more than two weeks before joining. They will be observed regularly for up to three years, with blood pressure measurements taken at baseline, 12, 24, and 36 months. The study also compares Nebilet used alone versus in combination with other treatments, and examines the relationship between blood pressure readings taken at home and in the clinic. Throughout the study, patients will have their blood pressure monitored, complete questionnaires about medication adherence and quality of life, and provide health information including cardiovascular risk factors and lab test results when available. Researchers will track major heart events like heart attacks and strokes, and record any side effects. Data will be collected electronically to ensure quality and consistency, helping to provide real-world insights about Nebilet's role in managing hypertension over time.

Researchers are studying the effects of Platelet Rich Plasma (PRP) added to pelvic organ prolapse repair surgery. The trial aims to see if PRP affects the type I/III collagen ratio and the levels of matrix metalloproteinases MMP-2 and MMP-9 during healing. Participants are women with pelvic organ prolapse who are postmenopausal and scheduled for surgery. Participants will be randomly assigned to receive either PRP or a placebo injection during their pelvic organ prolapse surgery. PRP is prepared from the patient's own blood drawn shortly before surgery, and the injection is given into the anterior vaginal mucosa at the pubocervical fascia area. A punch biopsy is taken during surgery and another biopsy is done 8 weeks after surgery to measure changes in collagen ratio and enzyme levels. During the study, participants will undergo medical history review, physical and pelvic exams, and muscle strength testing before surgery. They will be hospitalized for surgery and monitored postoperatively, with biopsies sent to a pathology lab for analysis. The main outcomes measured are changes from enrollment to 8 weeks after surgery in type I/III collagen ratio, MMP-2, and MMP-9. The study monitors safety and tissue changes over this 8-week treatment period.